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PolyfunctionalityHIV-1 speciﬁc HLA-B-restricted CD8+ T cell responses differ from HLA-C-restricted responses in antiviral
effectiveness. To investigate possible reasons for these differences, we characterized the frequency and
polyfunctionality of immmunodominant HLA-B*57/B5801- and HLA-Cw*07-restricted CD8+ T cells
occurring concurrently in nine study subjects assessing IFN-γ, TNF-α, IL-2, MIP-1β, and CD107a by ﬂow
cytometry and analyzed sequence variation in targeted epitopes. HLA-B*57/5801 and HLA-Cw*07 restricted
CD8+ T cells did not differ signiﬁcantly in polyfunctionality (p=0.84). Possession of three or more functions
correlated positively with CD4+ T cell counts (r=0.85; p=0.006) and monofunctional CD8+ T cells
inversely correlated with CD4 cell counts (r=−0.79; p=0.05). There were no differences in
polyfunctionality of CD8+ T cells speciﬁc to wildtype versus mutated epitopes. These results suggest that
loss of polyfunctionality and increase in monofunctional HIV-1-speciﬁc CD8+ T cells are associated with
disease progression independent of restricting HLA allele. Furthermore, sequence variation does not appear
to signiﬁcantly impact CD8+ T cell polyfunctionality in chronic HIV-1 infection.arch Institute, University of
1, South Africa. Fax: +27 31
 license. © 2010 Elsevier Inc. Open access under CC BY license. Introduction
HIV-speciﬁc CD8+ T cells play a vital role in the control of HIV
replication and disease progression (Altfeld et al., 2006; Borrow et al.,
1994; Koup et al., 1994; Schmitz et al., 1999). However, differences
exist in their antiviral effectiveness based on their HLA restriction,
epitope speciﬁcity, functional epitope avidity and targeted viral
protein (Bennett et al., 2007; Bihl et al., 2006; Kiepiela et al., 2007).
In particular, major histocompatibility complex (MHC) class I
molecules have been shown to differ in their ability to mediate the
control of HIV and SIV replication in humans and non-human
primates respectively (Goulder and Watkins, 2008; Kiepiela et al.,
2004). For example, virus-speciﬁc Gag CD8+ T cell responses
restricted by HLA-B*57, HLA-B*5801 and HLA-B*27 are associated
with low viral loads or slow disease progression in HIV infection
(Kiepiela et al., 2007; Klein et al., 1998; Migueles and Connors, 2001;
Novitsky et al., 2003) while Mamu-A*01 and Mamu-B*17 restricted
responses are associated with control in SIV infection of rhesusmacaques (Chung et al., 2007; Loffredo et al., 2007; Maness et al.,
2008; Migueles et al., 2003).
In contrast to the beneﬁcial outcomes associated with the
protective MHC allele-restricted Gag CD8+ T cell responses, Gag
HLA-C-restricted CD8+ T cell responses were found to be associated
with high viral loads (Kiepiela et al., 2007). Paradoxically, although
HLA-C-restricted CD8+ T lymphocytes appear to contribute little or
even negatively to viral control in vivo, HLA-C is not down-regulated
by HIV-1 Nef from the surface of infected cells to the same extent that
HLA-A and HLA-B molecules are (Cohen et al., 1999; Collins et al.,
1998). Overall, the mechanisms underlying control of HIV by
protective alleles such as HLA-B*57/5801, or the lack of control by
HLA-C alleles remain unclear and this limited understanding has
important implications for rational vaccine design.
HIV-speciﬁc CD8+T cells may also display different differentiation
status and activation proﬁles (Appay and Sauce, 2008; Papagno et al.,
2004). It has been suggest that these phenotypic differences are
associated with divergent functional antiviral capacities of virus-
speciﬁc T cells (Almeida et al., 2009). Some studies have suggested
that polyfunctional CD8+ T cells, able to secrete up to ﬁve different
effector functions (IFN-γ, IL-2, TNF-α, MIP-1β and CD107a), have
better antiviral activity (Betts et al., 2006; Daucher et al., 2008;
Precopio et al., 2007). CD8+ T cell responses restricted by HLA-B*27
484 N. Mkhwanazi et al. / Virology 405 (2010) 483–491and HLA-B*57 alleles were reported to be polyfunctional when
compared to CD8+ T cell responses restricted by HLA-A alleles
within the same patients (Harari et al., 2007). However, recent data
have suggested that the functional proﬁle of CD8+ T cells is largely a
consequence of the duration and level of antigen load, with prolonged
continuous exposure to high levels of antigen resulting in exhausted
CD8+ T cells characterized by a monofunctional effector proﬁle (Rehr
et al., 2008; Streeck et al., 2008a).
Here, we studied the polyfunctionality proﬁles of immunodomi-
nant HLA-B and HLA-C-restricted CD8+ T cells in a cohort of HIV-1
clade C chronically infected individuals displaying both responses.
This provided the unique opportunity to examine HLA-B and C
restricted responses in the context of matched viral loads and CD4 cell
counts. We focused on the immunodominant HLA-B*57/*5801
epitopes in Gag p24 and the immunodominant HLA-Cw*07 restricted
epitope KY11 in Nef, in persons possessing both responses. We
hypothesized that HLA-B CD8+ T cells will display a more polyfunc-
tional phenotype compared to HLA-C-restricted CD8+T cells. We also
aimed to determine whether sequence variation within epitopes
presented by these two alleles has a bearing on the magnitude and
polyfunctionality of epitope-speciﬁc CD8+ T cell responses. The
relationship between the frequency of polyfunctional HIV-1-speciﬁc
CD8+ T cells and CD4+ T cell counts and viral loads was also
investigated.Results
Characteristics of study subjects
The study subjects were seven females and two males, with a
median age of 40 (range 27–58) years, all coexpressing HLA-B*57/
5801 and Cw*07. The subjects were selected on the basis of possession
of concurrent dominant HLA-B*57/5801 and HLA-Cw*07 restricted
HIV-1 speciﬁc CD8+ T cell responses≥500 SFC/106 on IFN-γ ELISPOT.
The median plasma viral load was 11,500 (range 2530–750,000) RNA
copies/ml and themedian CD4 countwas 271 (range 202–411) cells/μl.
The subject gender, age, CD4 count, viral load, HLA type and epitopes
examined for each subject are shown in Table 1. These subjects were
selected from the Sinikithemba cohort, which compromised of 451
HIV-1 infected individuals whose time of infection was unknown. In
the cohort, 37 of 451 (8.2%) participants coexpressed HLA-B*57/5801
and HLA-Cw*07, 51 (11.3%) expressed HLA-B*57/5801 without HLA-
Cw*07 and 81 (18%) expressed HLA-Cw*07 without HLA-B*57/5801.
The median age CD4 cell count and viral load for the 37 subjects who
coexpressedHLA-B*57/5801 andHLA-Cw*07was 37 years, 490 cells/μl
and 6700 copies/ml respectively. Of these 37 individuals only the nine
further studied here had concurrent immunodominant HLA-B*57/
5801- and HLA-Cw*07-restricted IFN-γ ELISPOT responses deﬁned as
≥500 SFC/106 PBMCs.Table 1
Characteristics of study subjects.
Patient ID Sex Age
(years)
CD4 count
(cell/ml)
Viral load
(copies/ml)
HLA type
SK 009 Male 32 291 47,000 A*2301/74 B*
SK 215 Female 35 202 34,800 A*6802/74 B*
SK 236 Female 37 411 9900 A*02/3002 B*
SK 251 Female 58 271 2530 A*02/3001 B*
SK 318 Female 27 370 3600 A*33/74B*07
SK 358 Female 42 264 750,000 A*0202/2301
SK 364 Female 38 305 11,500 A*02/3001 B*
SK 379 Male 44 267 4310 A*0205/0208
SK 428 Female 45 214 272,000 A*0205/0208
Median 38 271 11,500Magnitude and breadth of HLA-B*57/5801 and HLA-C restricted
responses by the IFN-γ ELISPOT assay
All subjects included in this study made HIV-speciﬁc CD8+ T cell
responses to known HLA-B*57/5801 and HLA-Cw*07 epitopes as
determined by IFN-γ ELISPOT (Fig 1A). Only a few individuals within
the Sinikithemba study cohort had responses≥500/106 SFCs for both
HLA-B*57/5801 and HLA-Cw*07; these high magnitude responses
were examined further in subsequent assays. The immunodominant
HLA-B*57/5801-restricted responses were to the following four
epitopes: TSTLQEQIAW (TW10), ISPRTLNAW (ISW9), QATQDVKNW
(QW10) and KAFSPEVIPMF (KF11). In contrast, only one HLA-C
response was targeted by the study subjects: KRQEILDLWVY (KY11)
restricted by HLA-Cw*07 (Fig 1A; Suppl. Table 1). The overall
magnitude of the responses targeted by HLA-Cw*07 restricted
epitopes was signiﬁcantly higher than the magnitude of HLA-B*57/
5801 restricted responses (p=0.0012, Mann–Whitney test; Fig 1B).
The nine study patients were representative of an additional 28
individuals (total n=37) (data not shown) with HLA-B*57/5801-
restricted responses in terms of breadth of positive IFN-γ epitope-
speciﬁc ELISPOT responses detected. ISPRTLNAW (ISW9) and
KAFSPEVIPMF (KF11) were dominantly presented by HLA-B*5703;
whereas the presentation of QW9 and TW10 was variable between
B*5702 and B*5801 and were least presented by HLA-B*5703
(Fig. 1C). Notably, none of the B*5702 subjects presented ISW9
and KF11.Functionality proﬁles of HLA-B*57/5801 and HLA-C restricted HIV-1
speciﬁc CD8+ T cell epitopes
Previous studies of long term non-progressors have shown that
HIV-1-speciﬁc CD8+ T cells restricted by protective alleles such as
HLA-B*57 and HLA-B*27, may be more polyfunctional than CD8+ T
cells restricted by other HLAs (Champagne et al., 2001; Harari et al.,
2007; Zimmerli et al., 2005). To determine the functionality of HIV-
speciﬁc CD8+ T cells restricted by alleles with different disease
outcomes (HLA-B*57/5801 and HLA-Cw*07); we assessed the
polyfunctionality of these responses in those who possessed them
concurrently.
HIV-speciﬁc CD8+ T cells polyfunctionality was evaluated using
multicolor ﬂow cytometry by simultaneous measurement of ﬁve
functions: IFN-γ, TNF-α, IL-2, MIP-1β, and CD107a as previously
described in other studies (Betts et al., 2006; De Rosa et al., 2004;
Streeck et al., 2008a). On single function gating (Supp. Fig. 1), IFN-γ
expression was lower on HLA-B*57/5801 than on HLA-Cw*07
restricted HIV-1 speciﬁc CD8+ T cell epitopes (p=0.06; Mann–
Whitney test) (Fig. 2A), consistent with ELISPOT data. A similar trend
was observed for the other individual functions although the
magnitude of other responses was lower than for IFN-γ.HLA-B*57/5801 epitopes HLA-C epitopes
1503/5702 Cw*0202/0701 TSTLQEQIAW (p24) KRQEILDLWVY(Nef)
0702/5703 Cw*07/07 ISPRTLNAW (p24) KRQEILDLWVY(Nef)
0801/5801 Cw*07/07 ISPRTLNAW (p24) KRQEILDLWVY(Nef)
4201/5801 Cw*07/1701 QATQDVKNW (p24) KRQEILDLWVY(Nef)
02/5703 Cw*07/07 KAFSPEVIPMF (p24) KRQEILDLWVY(Nef)
B*08/5701 Cw*07/07 ISPRTLNAW (p24) KRQEILDLWVY(Nef)
4201/5801 Cw*07/1701 QATQDVKNW (p24) KRQEILDLWVY(Nef)
B*0702/5801 Cw*07/07 TSTLQEQIAW (p24) KRQEILDLWVY(Nef)
B*1401/5801 Cw*07/08 TSTLQEQIAW (p24) KRQEILDLWVY(Nef)
Fig. 1.Measurement of HLA-B*57/5801 and HLA-Cw*07-restricted T cell responses by Interferon-gamma ELISPOT assay. (A) Hierarchy of dominant epitopes presented by the study
subjects expressing HLA-B*57/5801 and HLA-Cw*07 alleles (n=9). Dotted line indicates responses above 500 SFCs from ELISPOT assay that were further tested in subsequent
multicolor assays. (B) Combined total magnitude of T cell responses presented by both HLA-B*57/B5801 and HLA-Cw*07 restricted epitopes in the study individuals (n=9). (C)
Percentage of epitope recognition (N100 SFCs/106 ELISPOT responses) of the dominant epitopes presented by different HLA-B57/5801 alleles (B*5701, B*5703 and B*5801) in all
chronically infected subjects coexpressing HLA-Cw*07 (n=37).
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(75%) in this study cohort were monofunctional (Fig. 2B). The most
frequently expressed function was MIP-1β at 40% for HLA-B*57/5801
and 30% for HLA-Cw*07, with CD107a at 30% for HLA-B*57/5801
restricted CD8+ T cells and 28% for HLA-C; and IFN-γ at 29 % for HLA-
B*57/5801 versus 30% for HLA-C. Monofunctional IL-2 or TNF-α
producing HIV-speciﬁc CD8+ T cells were very infrequent in this
cohort of chronically infected patients and only a small proportion of
HIV-speciﬁc CD8+ T cells expressed TNF-α responses conﬁrming
previous studies that this effector function is lost early in infection
(Lichterfeld et al., 2004; Wherry et al., 2003).
To further investigate potential differences in functional proﬁles
upon stimulation with both HLA-B*57/5801- and HLA-Cw*-restricted
peptides on all patients, we compared the frequencies of the different
HLA-restricted CD8+ T cells expressing different functions detected
in these individuals. The fraction of each function was determined as a
percentage of the total CD8+ T cell response as previously described
(Streeck et al., 2008b). No signiﬁcant differences were observed
between HLA-B*57/5801- and HLA-Cw*-restricted responses with
regard to ﬁve (p=0.64; Mann–Whitney test), four (p=0.89), three
(p=0.87), two (p=0.22) and one function (p=0.37) (Fig. 2B).
Taken together, these data suggest the differences in disease outcome
observed for HLA-B*57/5801 and HLA-Cw* cannot be explained by
the polyfunctionality of the HIV-speciﬁc CD8+ T cell responses during
chronic infection. In addition, polyfunctionality of CD8+ T cell
responses may not depend on the restricting HLA allele during the
chronic phase of infection.Relationship between the polyfunctionality of HLA-restricted HIV-1
speciﬁc CD8+ T cells, CD4 counts and viral loads
Previous studies have suggested that HLA-B-restricted HIV-1-
speciﬁc CD8+ T cells are more polyfunctional than HLA-A and HLA-C
(Harari et al., 2007; Zimmerli et al., 2005) and that the proportion of
the HIV-1-speciﬁc CD8+ T cell with the highest functionality
inversely correlate with viral loads in non-progressive(Betts et al.,
2006). The proportion of HIV-1-speciﬁc CD8+ T cell responses were
plotted against CD4 counts and viral load, for all the functions
(Figs. 3A and B). Since no differences were noted in polyfunctionality
proﬁles of HLA-B*57/5801 and Cw*07-restricted epitopes, the total
percentages across different (1–5) functions were added together to
determine whether or not there was a relationship between the
polyfunctional CD8+ T cells, viral load and CD4 counts. We noted a
signiﬁcant positive correlation between 3 or more functions and CD4
counts (p=0.006; r=0.85, Spearman test) (Fig. 3A). In contrast,
there was a negative correlation between monofunctional cells and
CD4 counts (p=0.05; r=−0.79). However, no correlation was noted
between the polyfunctional or monofunctional CD8+ T cells and viral
loads (Fig 3B).
Sequence variation within HLA-B*57/5801 and HLA-C restricted
epitopes and its impact on CD8+ T cell polyfunctionality
Sequence variation and the accumulation of mutations over course
of infection are known to affect epitope recognition, speciﬁcity of the
Fig. 2. Assessment of HIV-1 speciﬁc CD8+ T cell polyfunctionality by multicolor staining for HLA-B*57/5801 and HLA-Cw*07-restricted epitopes. (A) Magnitude of HLA-B*57/5801
and HLA-C restricted epitope responses usingmulticolor staining, single CD8+ T cell function responses are shown after background subtraction. (B) Comparison of the contribution
of individual functions between HLA-B*57/B5801 (○) and HLA-C (●) restricted epitopes in the study subjects (n=9). The fractions of the response patterns are grouped and color-
coded by the number of functions and summarized in pie chart form where each slice of the pie represents the fraction of the total epitope-speciﬁc response that consist of CD8+ T
cells with the respective number of functions.
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Nixon et al., 1988).Next, we evaluated whether the low magnitude of
responses noted in HLA-B*57/5801 compared to high HLA-Cw*07-
restricted CD8+ T cell responses was due to the sequence variation in
the CD8+ T cell epitopes. Gag and nef genes were sequenced in all
nine patients as the epitopes studied here were located in these viral
proteins. HLA-B*57/5801-restricted HIV-1-speciﬁc CD8+ T cell
epitopes had more sequence variation (6/9) when compared to
HLA-Cw*07-restricted epitopes (1/9), (p=0.05; Fisher's exact test),
despite the fact that the HLA-C-restricted response examined is in the
highly variable Nef protein. Themost frequent sequence changeswere
noted in the TSTLQEQIAW (TW10) and ISPRTLNAW (ISW9) Gag
epitopes restricted by HLA-B*57/5801, and a single sequence
variation was noted in the Nef Cw*07-restricted epitope
KRQEILDLWVY (KY11) restricted by HLA-Cw*07 (Table 2). These
data suggest that HLA-B*57/5801-restricted epitopes have highsequence variation compared to HLA-Cw*07-restricted epitopes and
this may in part account for the low magnitude of HLA-B*57/5801-
compared to HLA-Cw*07-restricted responses.
We also investigated whether or not sequence variation impacted
on CD8+ T cell polyfunctionality. CD8+ T cell polyfunctionality was
assessed by comparing HLA-B and HLA-C-restricted HIV-1-speciﬁc
CD8+ T cell epitopes with or without the sequence variation against
the percentage of the total HIV-1-speciﬁc CD8+ T cell response
(Fig. 4). No differences were noted between epitopes with or without
sequence variationwith regard to 3 ormore functions, 2 functions and
monofunctional T cells. However, there was a high frequency of
monofunctional HIV-1-speciﬁc CD8+ T cells when compared to other
functions e.g. monofunctional HLA-B*57/5801 epitopes with or
without sequence variation were higher than HLA-B*57/5801
epitopes with or without sequence variation expressing 3 or more
functions (p=0.004, p=0.10 respectively, Mann–Whitney test).
Fig. 3. Relationship between the fractions ofmonofunctional, bi-functional and polyfunctional HIV-1 speciﬁc CD8+T cell responses and the (A) CD4+T cell counts and (B) viral loads.
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restricted responses compared to HLA-Cw*07-restricted CD8+ T cell
responses may have been due to sequence variation, these data imply
that sequence variation alone may not affect the polyfunctionality of
HLA-B*57/5801 or HLA-Cw*07 restricted HIV-1-speciﬁc CD8+ cells.
Discussion
Themechanisms underlying better control of HIV-1 by certain HLA
alleles are not well understood. Understanding these mechanisms
could facilitate the rational design of an effective HIV-1 vaccine. We
therefore here investigated the functional characteristics of CD8+ T
cells responses restricted by either HLA-B*57/5801 or HLA-Cw*07
alleles within the same individuals in order to better understand the
differences in disease outcome mediated by these two alleles.
We show that IFN-γ producing CD8+T cell responses restricted by
HLA-Cw*07 were signiﬁcantly higher than responses mediated by
HLA-B*57/5801, both on ELISPOT and intracellular cytokine staining
(Figs. 1B and 2A). As shown in Fig 1C, the targeted responses in the
nine study subjects were representative of other HLA-B*57/5801-
possesing persons in the larger cohort. However, the nine study
participants were in a relatively advanced stage of infection, as
evidenced by the lowmedian CD4+ T cell count of 288 cells/μl, and it
is possible that this disease progression status may have inﬂuencedTable 2
Sequence variation in CD8+T cell epitopes presented by HLA-B*57/B5801 and HLA-Cw*07
Highlighted-epitopes tested in ICS.
Unhighlighted-epitopes not tested in ICS.the magnitude of HLA-B*57/5801-restricted responses relative to
HLA-C responses. On the other hand, the more obvious explanation of
the high magnitude of HLA-C-restricted responses is the higher
conservation of these epitopes compared to the escaped HLA-B*57/
5801-restricted epitopes (Table 2). We also noted that in the
Sinikithemba cohort from which the nine participants studied here
were selected, there was signiﬁcantly higher B*57/5801-restricted
responses in individuals coexpressing HLA-Cw*07 compared to those
HLA-B*57/5801-positive subjects who do not express HLA-Cw*07
(data not shown). Also, Cw*07 restricted responses were signiﬁcantly
higher in those coexpressing B*57/5801 compared to those not
expressing B*57/5801. These data suggest that there may be some
interactions between these alleles that inﬂuence the magnitude of
immune responses. Further studies will be needed to address whether
there are differences in polyfunctionality of T cells restricted by these
alleles in individuals coexpressing them versus those expressing one
allele without the other.
We hypothesized here that protective HLA-B restricted CD8+ T
cells have a more polyfunctional proﬁle compared to the non-
protective HLA-C-restricted responses as has been described in
some studies (Betts et al., 2006; De Rosa et al., 2004). In contrast to
these earlier studies, we found no signiﬁcant differences in polyfunc-
tional CD8+ T cell responses mediated by the two alleles within
patients with both responses (Fig. 2B). Whereas in the other studiesalleles.
Fig. 4. Evaluation of the relationship between epitope sequence variation and polyfunctionality of HIV-speciﬁc CD8+ T cell responses. HLA- B*57/5801 and HLA-Cw*07 restricted
epitope responses with andwithout sequence variationwere plotted against the percentage of total HIV-1 speciﬁc CD8+ T cells with≥3 functions, bi-functional andmonofunctional
CD8+ T cell responses generated from the study individuals (n=9).
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responses occurring concurrently within a patient thus eliminating
confounding by disease status, environmental and genetic factors. We
observed a positive correlation between polyfunctionality and CD4+
T cell count, but no correlation with viral load suggesting that disease
progression but not viral antigen load per se is associated with loss of
CD8+ T cell polyfunctionality (Fig. 3A). The lack of correlation
between the polyfunctionality of HIV-1 speciﬁc CD8+ T cells and viral
load is in contrast to results from earlier studies (Betts et al., 2006;
Daucher et al., 2008) and it is possible that the small sample size in our
study and the relatively advanced phase of infection for all the study
subjects reducing the power to detect differences. We also observed an
inverse correlation between the proportion of monofunctional CD8+ T
cells and CD4+ T cell counts, which suggests that immune dysfunction
as seen in late chronic HIV-1 infection is characterized by increasing
proportion of exhausted monofunctional cells.
It was recently observed in a longitudinal study of recent HIV-1
infection that CD8+ T cells directed against conserved epitopes lost
their polyfunctionality whereas escaping-epitope targeting CTLs
appeared to maintain their original polyfunctional proﬁle (Streeck
et al., 2008a). We investigated here whether there were sequence
variation differences in HLA-B*57/5801 versus HLA-Cw*07-restricted
epitopes and whether such differences resulted in divergent CD8+ T
cell polyfunctionality proﬁles HLA-B*57/5801-restricted epitopes
were more variable, perhaps suggesting increased immune selection
pressure on these epitopes, however, there were no differences
observed in polyfunctionality between these and immunodominant
HLA-Cw*07 restricted CD8+ T cells. Although limited by small sample
size, these data imply that sequence variation in targeted epitopes
may have no impact on the level of polyfunctionality of CD8+ T cells
during chronic HIV-1 infection, although as shown previously,
sequence variation within a targeted epitope can impact on
polyfunctionality over time (Streeck et al., 2008b). We emphasize
that our results should not be interpreted to be contradicting those of
Streeck and colleagues given the differences in study design; here we
used a cross-sectional design to analyze polyfunctionality differences
in CD8+ T cells to conserved versus variable epitopes compared to
longitudinal follow-up of escaping or non-escaping epitopes in the
earlier study. Furthermore, in the current study we cannot tell how
long the sequences noted for the epitopes had existed in the patients
without undergoing changes, a factor that may affect polyfunction-
ality. In addition, the population sequencing strategy we employedmay limit the detection of all variants present in the study subjects. It
is also possible that not all escape mutants have the same impact, in
some cases variants continue to be partially recognized and a CD8+ T
cell response is maintained whilst in other cases, for example where
HLA-binding is abrogated, the CD8+ T cell response falls to very low
levels. We speculate that the result of these two extremes on
polyfunctionality would differ considerably, such that partial reduc-
tion in epitope recognitionwould decrease or otherwise change CD8+T
cell polyfunctionality minimally, whereas more complete loss of
epitope recognition would signiﬁcantly increase CD8+ T cell
polyfunctionality.
The strength of this study is that CD8+ T cells were analyzed
concurrently within study subjects with both responses of interest,
thus eliminating across subject confounders. However, limitations
include a small sample size and relatively advanced phase of infection
of study subjects. We also did not measure CD8+ T cell antiviral
function directly and are thus unable to conclude whether poly-
functionality had any association with antiviral functional capacity.
In summary, we found that in late chronic HIV-1 infection,
immunodominant HLA-B*57/5801 restricted IFN-γ CD8+ T cell
responses were of lower magnitude compared to immunodominant
HLA-Cw*07-restricted responses in patients with both responses
possibly due to differences in sequence variation in targeted epitopes.
We did not ﬁnd evidence of polyfunctionality differences between
HLA-B*57/5801 versus HLA-C-restricted CD8+ T cells. Polyfunction-
ality of CD8+ T cells correlated positively with CD4 T cell counts,
suggesting that either polyfunctionality is lost as disease progresses or
that loss of polyfunctionality leads to disease progression. There was
no impact of sequence variation within targeted epitopes on the
polyfunctionality of restricted CD8+ T cells. Larger longitudinal
studies are needed to better elucidate the mechanisms that underlie
protective versus non-protective HLA-mediated CD8+ T cell
responses.
Materials and methods
Study subjects
Nine HIV-1 infected patients were selected for this study from the
Sinikithemba cohort, a prospective natural history study of HIV-1
chronically infected, antiretroviral naïve individuals, established in
2003 at McCord Hospital, Durban, South Africa (Kiepiela et al., 2004;
489N. Mkhwanazi et al. / Virology 405 (2010) 483–491Kiepiela et al., 2007). In this study population, Cw*0701 is in linkage
disequilibrium with B*5801 (p=0.0239) and B*5703 (p=0.0097)
and B*5702 (p=0.0034) as determined by the HLA linkage
disequilibrium tool on the Los Alamos HIV database (http://www.
hiv.lanl.gov/content/immunology/hla/hla_linkage.html). In B*5702/
5703-positive subjects, 64% coexpress Cw*07, and in B*5702/5703-
positive subjects who do not express Cw*0701, 97% coexpress
Cw*1801. In B*5801-positive subjects, 65% coexpress Cw*07 and in
88% of the remainder either Cw*0302 or Cw*0602 are coexpressed
with B*5801.
The nine subjects studied here were selected based on the
possession of concurrent immunodominant HLA-B*57/5801- and
HLA-Cw*07-restricted CD8+ T cell responses detected by gamma
interferon (IFN-γ) ELISPOT, deﬁned as a minimum magnitude of 500
spot forming cells per million (SFC/million) PBMC for each of these
responses.
Viral load and CD4 counts measurement
Viral loads (VL) were determined from plasma using Roche
Amplicor (version 1.5) and CD4+ T cell counts were enumerated
from fresh blood by Tru-Count technology using a four-color
FacsCalibur ﬂow cytometer (Becton Dickinson) as previously de-
scribed (Ngumbela et al., 2008; Thobakgale et al., 2007).
HLA typing
DNA for HLA typing was isolated using Puregene DNA isolation kit
for blood (Gentra systems, Minneapolis, MN) according to the
manufacturer's instructions. HLA class I typing was done by DNA
PCR using sequence-speciﬁc primers as described before (Kiepiela et
al., 2004; Thobakgale et al., 2009).
Synthetic HIV-1 peptides and Interferon-γ ELISPOT assay
A panel of 410 overlapping peptides (18mers with 10–12 amino
acid overlap) spanning the entire HIV-1 clade C consensus sequence
were synthesized and used in matrix screening assays as previously
described (Goulder et al., 2001; Kiepiela et al., 2004). Previously
deﬁned optimal peptides were similarly synthesized. Ex vivo mea-
surement of T cells for IFN-γ production was undertaken by the
ELISPOT assay as previously reported (Kiepiela et al., 2004; Ngumbela
et al., 2008; Thobakgale et al., 2009). The antigen-speciﬁc T cell
responses were considered positive if they were N100 SFC above the
unstimulated negative control wells.
Polyfunctionality analysis by multicolor ﬂow cytometry
Ex vivomeasurement of CD8+ T cells for expression of IFN-γ, IL-2,
MIP-1β, TNF-α and CD107a was assessed by multicolor ﬂow analysis
as previously described (Streeck et al., 2008a). In brief, freshly thawed
cryopreserved PBMCs were resuspended to 1–2×106 cells/ml in R10
media (RPMI 1640 supplemented with 10% heat-inactivated FCS,
100 U/ml penicillin, 1.7 mM sodium glutamate, 5.5 ml HEPES buffer)
and rested for 2 h at 37 °C and 5% CO2. One million cells/ml were
stimulated with optimal HLA-B*57/5801 or HLA-Cw*-restricted
peptides that represented immunodominant (≥500 SFC on ELISPOT)
responses in the study subjects (Fig. 1A) in the presence of anti-CD28
and anti-CD49 co-stimulatory antibodies. A negative control with
PBMCs alone and a positive control containing PBMCs stimulated with
Staphylococcus enterotoxin B (SEB) were included in the assays. Anti-
CD107a-PE-Cy5 (BD Biosciences) antibody was added and incubated
for 30 min at 37 °C, 5% CO2, followed by addition of Brefeldin A (10 μg/
ml, Sigma-Aldrich, St Louis, MO) and Monensin (2.5 μg/ml, Sigma-
Aldrich) and incubated at 37 °C, 5% CO2 for total of 6 h. The cells were
then washed with PBS (2% FCS), stained to differentiate between live/dead cells (violet viability dye, Invitrogen) and incubated for 30 min
at 4 °C. Cells were then washed and stainedwith the following surface
antibodies: anti-CD3-PE Cy5.5 (Caltag), CD4-APC, CD8-APC Cy7 (both
from BD Biosciences) and incubated for 20 min in the dark at room
temperature. Cells were again washed and ﬁxed in 1% paraformalde-
hyde (Fix Perm A, Caltag) for 20 min in the dark at room temperature
and were then permeabilized (Fix Perm B, Caltag) and stained
intracellularly with the following antibodies: anti-IFN-γ PE Cy7, anti-
TNF-α Alexa 700, anti-MIP-1β PE, anti-IL-2 FITC (all from BD
Biosciences) before incubation for 20 min in the dark at room
temperature. The cells were washed twice with PBS and resuspended
in 200 μl of PBS before acquisition on LSRII ﬂow cytometer
(BD Bioscience).
Sample acquisition and analysis
Between 200,000 and 1,000,000 events were collected per sample.
Analysis was performed using DIVA and FlowJo 8.3.3 software
(TreeStar, Ashland, OR). Initial gating was on the lymphocytes
population, then forward scatter height (FSC-H) versus forward
scatter area (FSC-A) to remove doublets (Supplementary Fig. 1).
Subsequently, live CD3+ T cells gating, followed by identiﬁcation of
CD8+ T cells was done; then individual gates (set based on the
negative control), for respective functions were made to identify
positive responses. Boolean gating was performed to create a full
array of possible combination of up to 32 response patterns. Positive
responses were reported after background correction and the
percentage of epitope-speciﬁc CD8+ T cell responses had to be at
least two times higher than background for each tested marker.
Analysis of multifunctional data was performed by PESTLE (version
1.6.2) and SPICE 5.0 (Mario Roederer, ImmunoTechnology Section,
Vaccine Research Center, NIH, Bethesda, MD).
Sequencing of Gag and Nef genes
HIV-1 RNA was extracted from 500 μl of plasma (VL b5000 HIV-1
RNA copies/ml) or 140 μl plasma (VL N5000 RNA copies) using QIAmp
viral RNA extraction kit (Qiagen). RNAwas reversed transcribed using
one-step RT-PCR kit (Invitrogen) and gene speciﬁc primers under the
following conditions: reverse transcription at 55 °C for 30 min,
followed by ampliﬁcation at 94 °C for 2 min, and 35 cycles of 94 °C
for 15 s, 55 °C for 30 s, 68 °C for 2 min; and ﬁnal extension at 68 °C for
5 min. Gag PCR primers were 5′-CTAGCAGTGGCGCCCGAACA-3′ and 5′
GCAGTCTTTCATTTGGTGTCCTCC-3′. The same primers were used in
the second round PCR reaction using the following conditions: 94 °C
for 2 min, followed by 35 cycles of 94 °C for 15 s, 58 °C for 30 s, 72 °C
for 1:30 min, with a ﬁnal extension at 72 °C for 7 min. Nef PCR primers
were 5′-TTCAGCTACCACCGATTGAGA-3′ and 5′-TGAGGGTTGGC-
CACTCC-3′. The PCR conditions were similar to those for gag except
for the second round PCR reaction, where the annealing temperature
was set at 56 °C for 30 s. Puriﬁed (Qiagen) PCR products were
sequenced using BigDye v3.1 Terminator sequencing kit (Applied
Biosystems, Foster city, CA, USA) on a XL-3100 automatic DNA
sequencer (Applied Biosystems). Nucleotide sequences were ana-
lyzed using Sequencer 4.8 software (GeneCodes Corporation, Ann
Arbor, MI). Alignments of reference and newly generated gag and nef
sequences were performed using ClustalX and edited by Bioedit
Sequence Alignment editor.
Statistical analysis
Mann–Whitney U test was used to compare the median magni-
tude of HLA-B versus HLA-C responses. The same test was used to
compare individual effector functions or polyfunctional responses
between HLA-B*57/5801 and HLA-C responses in individuals. The
Spearman rank correlation test was used to correlate individual and
490 N. Mkhwanazi et al. / Virology 405 (2010) 483–491polyfunctional responses with viral loads and CD4 counts. Fisher's
exact test was used to compare proportions of HLA-B and HLA-C
epitopes with sequence variation.
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